SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MasTec Q3 Earnings & Revenues Beat Estimates on Power Delivery Strength

MTZ's Q3 earnings and revenues beat estimates on Power Delivery strength and record backlog, but pipeline delays prompt a cut to its 2026 profit outlook.

PWR Q3 Earnings Beat on Electric Strength, 2026 View Raised, Stock Up

Quanta's Q3 2026 earnings and revenues beat estimates, fueled by electric infrastructure demand, as record backlog drives a higher 2026 outlook.

Quanta Services (PWR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Quanta Services (PWR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Quanta Services (PWR) Q3 Earnings and Revenues Beat Estimates

Quanta Services (PWR) delivered earnings and revenue surprises of +20.48% and +9.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Ideas feature highlights: Quanta Services

Quanta Services has fallen 25% ahead of Q3 earnings, but record backlog, rising earnings estimates and AI-driven energy infrastructure demand could support long-term growth.

Quanta Services Inc. Profit Climbs In Q3

(RTTNews) - Quanta Services Inc. (PWR) announced earnings for its third quarter that Increases, from last year...

QUANTA SERVICES REPORTS THIRD QUARTER 2026 RESULTS

QUANTA SERVICES REPORTS THIRD QUARTER 2026 RESULTS QUANTA SERVICES REPORTS THIRD QUARTER 2026 RESULTSPR NewswireHOUSTON, Oct. 29, 2026 Third Quarter Consolidated Revenues of $12.0 Billion*Third Quarter GAAP Diluted EPS of $4.55* and Adjusted Diluted EPS of $6.06*Net Income Attributable to Common...

Meritage Homes (MTH) Lags Q3 Earnings and Revenue Estimates

Meritage (MTH) delivered earnings and revenue surprises of -5.93% and -10.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Best Stocks to Buy Now Before Earnings and Hold: PWR 

Quanta Services (PWR) is one of the best pure-play stocks to buy to benefit from the artificial intelligence-driven energy boom.

3 Reasons Why Growth Investors Shouldn't Overlook Quanta Services (PWR)

Quanta Services (PWR) could produce exceptional returns because of its solid growth attributes.

$PWR Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $6.06 up 81.98% YoY
• Reported revenue of $12.01B up 57.44% YoY
• Quanta Services now expects full-year 2026 revenue of $41.3B to $41.6B, adjusted diluted EPS of $17.90 to $18.30, and free cash flow of $2.5B to $3B.

Stocktwits

Quanta Services, Inc.

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $6.06 up 81.98% YoY
• Reported revenue of $12.01B up 57.44% YoY
• Quanta Services now expects full-year 2026 revenue of $41.3B to $41.6B, adjusted diluted EPS of $17.90 to $18.30, and free cash flow of $2.5B to $3B.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $6.06 up 81.98% YoY
• Reported revenue of $12.01B up 57.44% YoY
• Quanta Services now expects full-year 2026 revenue of $41.3B to $41.6B, adjusted diluted EPS of $17.90 to $18.30, and free cash flow of $2.5B to $3B.

Quanta Services faces weather, regulatory, permitting and supply-chain factors affecting project execution, potential delays or cancellations that shift revenue timing, and competition or technological developments that could reduce demand.

Quanta Services delivered strong double-digit growth in revenue, adjusted EBITDA and adjusted diluted EPS, reached record $63.7B backlog amid broadening demand, and completed acquisitions to strengthen front-end, fabrication and supply chain capabilities.

Quanta Services, Inc. engages in the provision of comprehensive infrastructure solutions to the electric power, oil and gas, communication, pipeline, and energy industries. It operates through the following segments: Electric Power, Renewable Energy, and Underground and Infrastructure. The Electric Power segment provides services for the electric power and communications markets. The Renewable Energy segment is involved in providing infrastructure solutions to customers involved in the renewable energy industry. The Underground and Infrastructure segment offers infrastructure solutions to customers involved in the transportation, distribution, storage, development, and processing of natural gas, oil, and other products. The company was founded by Kevin D. Miller, Steven P. Colmar, William G. Parkhouse, and John R. Colson on August 19, 1997 and is headquartered in Houston, TX.

GEV, D, CMS, AEP And PWR To Report Earnings This Week – A Look At What Investors Are Watching

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>GE Vernova and Quanta Services enter Q3 earnings with backlogs of $176 billion and $53.4 billion, respectively.</li><li>GEV and PWR have the biggest upside potential based on 12-month price targets compiled on Koyfin.</li><li><a class="mention" data-mention="$D" data-symbol-id="D" href="https://stocktwits.com/symbol/D" target="_blank">Dominion Energy</a>’s Q3 results will put the spotlight on its proposed $66.8 billion merger with NextEra Energy.</li></ul><p>With third-quarter earnings in full swing, major utility firms are expected to report their results this week, with Wall Street looking for clues on whether rising electricity demand from AI data centers is translating into bigger backlogs and a stronger bottom line.</p><p>However, the earnings also come amid growing concerns about electricity affordability and the cost of new power generation.</p><p>CMS Energy (CMS), GE Vernova (GEV), American Electric Power (AEP), Quanta Services (PWR), and Dominion Energy (D) are expected to report earnings this week.</p><p><img src="https://news.stocktwits-cdn.com/Np_Om_L_q3_estimates_0425709196.png" alt="NpOmL-q3-estimates-.png"></p><h2 class="st-heading-2">CMS’ $24B Plan In Focus</h2><p>CMS Energy kicks off earnings this week, with analysts expecting revenue of $2.18 billion and earnings per share (EPS) of $1.35, compared with $2.02 billion and EPS of $0.93 in the prior-year quarter, according to Fiscal.ai.</p><p>The Michigan-based utility reaffirmed its 2026 adjusted EPS outlook of $3.83 to $3.90 in July.</p><p>Recent updates include <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/201533/000110465926087288/tm2621427d1_ex99-1.htm">plans</a> to exit non-utility renewable-energy development under NorthStar Clean Energy to focus on utility business. Its Consumers Energy subsidiary also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmsenergy.com/investor-relations/news-releases/news-release-details/2026/Consumers-Energy-Plan-Will-Power-Michigans-Next-Generation-with-Reliable-and-Affordable-Energy/default.aspx">unveiled</a> a 20-year electricity supply plan that combines natural gas, solar, wind, and energy storage. CMS is expected to invest more than $24 billion in the plan through 2030.</p><p>Key updates to watch include the $24 billion investment program and the financial impact of its NorthStar restructuring.</p><h2 class="st-heading-2">GEV’s Backlog Continues To Grow</h2><p>Wall Street expects GE Vernova to report revenue of $11.99 billion and EPS of $4. The company reported Q3 2025 revenue of $9.97 billion and EPS of $1.64. GE Vernova <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gevernova.com/news/articles/ge-vernova-releases-second-quarter-2026-financial-results">raised</a> its full-year (FY) 2026 revenue guidance to $45.5 billion to $46.5 billion in July and expects an adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin of 12% to 14%.</p><p>Investors will seek updates on its backlog, which stood at $176 billion in the previous quarter, order pricing, and updates on its wind business.</p><p>Susquehanna recently maintained a ‘Positive’ rating on the stock, citing growing power demand as the sector’s main catalyst.</p><h2 class="st-heading-2">AEP’s Power Supply Plans In View</h2><p>AEP is expected to post revenue of $6.60 billion and EPS of $2.04, up from $6.01 billion and $1.80 a year earlier. AEP raised its 2026 operating EPS guidance to $6.25 to $6.55 in July, citing its $78 billion five-year capital investment plan.</p><p>The utility also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.aep.com/news/stories/view/12135/">expanded</a> its contracted new electricity load additions to 69 GW through 2030 and secured 13 GW of gas turbine capacity, with another 10 GW under evaluation.</p><p>Investors will look for updates on these agreements, progress on power generation projects, and the company’s power supply plans in light of the Pennsylvania-New Jersey-Maryland Interconnection (PJM) proposed electricity procurement reforms.&nbsp;&nbsp;</p><h2 class="st-heading-2">Quanta To Post Strong Top-Line Growth</h2><p>Analysts expect Quanta to report $10.91 billion in revenue compared with $7.63 billion last year and EPS of $5 from $3.33. Quanta also expects FY2026 revenue of $39.3 billion to $39.7 billion and EPS of $16.45 to $16.95.</p><p>Its second-quarter <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.quantaservices.com/news-events/press-releases/detail/402/quanta-services-reports-second-quarter-2026-results">results</a> showed a record backlog of $53.4 billion. The company also completed acquisitions of Phalcon and Enerfab earlier this year, expanding its electrical, mechanical and industrial construction capabilities. Investors will look for updates on backlog growth.</p><h2 class="st-heading-2">Dominion-NEE Deal Remains Key Trigger</h2><p>Dominion’s Q3 revenue is expected to come in at $4.74 billion with EPS of $1.21, compared with $4.53 billion and $1.06 a year earlier. Dominion forecast FY2026 EPS guidance of $3.45 to $3.69.</p><p>A major focus will be progress on its proposed $66.8 billion combination with NextEra Energy (NEE), which remains subject to regulatory approvals.</p><p>Investors will also keep an eye on construction progress at Dominion’s 2.6 GW Coastal Virginia Offshore Wind project. Its latest quarterly filing estimated costs at $11.7 billion, with final turbine installations expected by the end of 2027.</p><p><img src="https://news.stocktwits-cdn.com/J6_ZCY_12_month_price_targets_399f1a49e1.png" alt="J6ZCY-12-month-price-targets-.png"></p><h2 class="st-heading-2">How Did GEV, CMS, PWR, AEP And D Stocks Fare Last Quarter?</h2><p>All five stocks ended Q3 in the red, with GE Vernova (GEV) falling 17.1% between July and September, CMS Energy slumped 16.9%, American Electric Power dropped 12.2%, Dominion Energy declined 10.7%, while Quanta Services edged 7.1% lower.</p><p><img src="https://news.stocktwits-cdn.com/Q3_Performance_5cd31cb61d.png" alt="Q3 Performance.png"></p><p>However, the stocks are in positive territory year to date. Quanta led the cohort with roughly 25% gains, followed by GE Vernova’s 20% rise. American Electric Power is up 12%, Dominion Energy has gained 10.6%, while CMS Energy edged 0.5% higher.</p><p><strong>Also read:</strong><a href="https://stocktwits.com/news-articles/markets/equity/lmt-rtx-lhx-hii-stocks-win-big-this-week-amid-pentagon-spending-ramp-up/cZUGPScRBU7"><strong>&nbsp;Stocktwits Defense Watch: Lockheed Martin, RTX, L3Harris, HII Add To Their Defense Contract Backlogs Amid Pentagon Spending Ramp-Up</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Investors will look for the impact of AI-driven electricity demand as power and utility companies face a crucial earnings week.

American Electric Power Company Inc.

CMS Energy Corporation

Dominion Energy Inc

GE Vernova Inc.

NextEra Energy Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$5.01	--	--	N/A
Q3 '26	$5.02	$6.06	20.71%	BEAT
Q2 '26	$3.31	$4.24	28.21%	BEAT
Q1 '26	$2.04	$2.68	31.50%	BEAT
Q4 '25	$3.05	$3.16	3.70%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

PWR Earnings

Latest Earnings Results: Q3 '26

Historical Earnings